Moreover, we have demonstrated LOX as a regulator of SSAO activity, VAP-1 protein and Aoc3 mRNA expression in early passage rat aortic VSMCs, highlighting SSAO as an important novel therapeutic target for the treatment/prevention of atherosclerosis [5]. Here, AOC3 is linked to atherosclerosis.